If you have been reading about c-Met receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
== Reconstitution and Combat Operations during 1944 == In late March 1943, the brigade was reformed behind enemy lines. By June 1944, the brigade became a primary target during Operation Cormoran, a massive German security operation aimed at clearing the rear areas of Army Group Centre. Archival reports from this period described a desperate struggle:
C6H5C(O)CH(NOSO2H) + 2 H2O → C6H5C(O)CHO + NH4HSO4 It may also be prepared from methyl benzoate by a reaction with potassium dimsyl to give an intermediate β-ketosulfoxide, which undergoes a Pummerer-type rearrangement, followed by oxidation by with copper(II) acetate. Alternatively, it can also be prepared by oxidation of acetophenone with selenium dioxide.
denotes the Kronecker delta. The physical interpretation of the various terms in the above master equation is straight forward: the terms on the first line describe the growth of fibrils via monomer addition with rate constant
Pituicytes from the posterior pituitary are glial cells with characteristics in common to astrocytes. Tanycytes in the median eminence of the hypothalamus are a type of ependymal cell that descend from radial glia and line the base of the third ventricle. Connective tissue is found in between other tissues and comprises connective tissue proper and special connective tissue. Most types of connective tissue consists of three main components: elastic and collagen fibers, ground substance, and cells. Connective tissue membranes include the synovial membrane, which lines the inner surface of capsules of synovial joints, tendon sheaths, and synovial bursas. Connective tissue proper includes loose (or areolar) and dense (regular and irregular) connective tissue. Adipose (Latin adeps, adip-, fat) and reticular connective tissue are regarded by older sources as forms of loose connective tissue alongside areolar tissue, while some newer sources have termed them as forms of special connective tissue. Special connective tissue includes supportive connective tissue (bone and cartilage) and fluid connective tissue (blood and lymph). Epithelial tissue are protective tissue that form the glands and outermost layer of many organs, including the skin (epidermis), internal organs (mesothelium), blood and lymphatic vessels (endothelium), as well as specialised organs (e.g. olfactory, respiratory, intestinal, transitional, vaginal, germinal (female), and germinal (male) epithelia).
Sources: en.wikipedia.org
Bronopol (INN; chemical name 2-bromo-2-nitropropane-1,3-diol) is an organic compound that is used as an antimicrobial. It is a white solid although commercial samples appear yellow. The first reported synthesis of bronopol was in 1897. Bronopol was invented by The Boots Company PLC in the early 1960s and first applications were as a preservative for pharmaceuticals. Due to its low mammalian toxicity at in-use levels and high activity against bacteria, especially Gram-negative species, bronopol became popular as a preservative in many consumer products such as shampoos and cosmetics. It was subsequently adopted as an antimicrobial in other industrial environments such as paper mills, oil exploration, and production facilities, as well as cooling water disinfection plants.
GLP requires not only that the methods of safety tests be transparent, but that they be so detailed that a different laboratory using it will get the same result. Considering that Japan, Netherlands, US and others had at same time as GLP begun requiring demonstrations of safety before chemicals gained access markets; the Organisation for Economic Cooperation & Development decided that multinational companies needed globally uniform regulation of chemicals, such that a toxicity test performed in one country could be accepted by another. OECD was thus happy to add the new USA GLP requirement into their new, globally-required test methods, called ‘OECD Test Guidelines’ (see below OECD section).
=== Vaporization === Ethnobotanist Daniel Siebert cautions that inhaling hot air can be irritating and potentially damaging to the lungs. Vapor produced by a heat gun needs to be cooled by running it through a water pipe or cooling chamber before inhalation.
Epitiostanol, also known as 2α,3α-epithio-4,5α-dihydrotestosterone (2α,3α-epithio-DHT) or as 2α,3α-epithio-5α-androstan-17β-ol, is a synthetic androstane steroid and a derivative of DHT. Mepitiostane, a derivative of epitiostanol with a C17α methoxycyclopentane ether substitution, is an orally active prodrug of epitiostanol. Another derivative, methylepitiostanol (2α,3α-epithio-17α-methyl-5α-androstan-17β-ol), has a methyl group at the C17α position and is similarly an orally active variant of epitiostanol; it has surfaced as a novel designer steroid.
=== Other factors === The prevalence of abdominal obesity is increasing in Western populations, possibly due to a combination of low physical activity and high-calorie diets, and also in developing countries, where it is associated with the urbanization of populations. Other environmental factors, such as maternal smoking, estrogenic compounds in the diet, and endocrine-disrupting chemicals may be important also. Hypercortisolism, such as in Cushing's syndrome, also leads to central obesity. Many prescription drugs, such as dexamethasone and other steroids, can also have side effects resulting in central obesity, especially in the presence of elevated insulin levels.
Sources: en.wikipedia.org
daltons. HDC differs from other types of chromatography because the separation only takes place in the interstitial volume, which is the volume surrounding and in between particles in a packed column. HDC shares the same order of elution as Size Exclusion Chromatography (SEC) but the two processes still vary in many ways. In a study comparing the two types of separation, Isenberg, Brewer, Côté, and Striegel use both methods for polysaccharide characterization and conclude that HDC coupled with multiangle light scattering (MALS) achieves more accurate molar mass distribution when compared to off-line MALS than SEC in significantly less time. This is largely due to SEC being a more destructive technique because of the pores in the column degrading the analyte during separation, which tends to impact the mass distribution. However, the main disadvantage of HDC is low resolution of analyte peaks, which makes SEC a more viable option when used with chemicals that are not easily degradable and where rapid elution is not important.
== External links == Shityakov, Sergey; Salvador, Ellaine; Pastorin, Giorgia; Förster, Carola (2015). "Blood-brain barrier transport studies, aggregation, and molecular dynamics simulation of multiwalled carbon nanotube functionalized with fluorescein isothiocyanate". International Journal of Nanomedicine. 10: 1703–1713. doi:10.2147/IJN.S68429. PMC 4356663. PMID 25784800.
=== Centre of Molecular Structure === Focuses on the structural and biophysical analysis of biological molecules. It is part of the Czech Infrastructure for Integrative Structural Biology (CIISB). The facility uses techniques including X-ray crystallography and small-angle X-ray scattering (SAXS), and offers biophysical methods for characterizing biomolecules.
The current reviewers identified a number of basic science research areas that could be helpful in resolving some of the controversies in the field, two of which were: 1) material science aspects of deuterated metals using modern characterization techniques, and 2) the study of particles reportedly emitted from deuterated foils using state-of-the-art apparatus and methods. The reviewers believed that this field would benefit from the peer-review processes associated with proposal submission to agencies and paper submission to archival journals. Cold fusion researchers placed a "rosier spin" on the report, noting that they were finally being treated like normal scientists, and that the report had increased interest in the field and caused "a huge upswing in interest in funding cold fusion research". However, in a 2009 BBC article on an American Chemical Society's meeting on cold fusion, particle physicist Frank Close was quoted stating that the problems that plagued the original cold fusion announcement were still happening: results from studies are still not being independently verified and inexplicable phenomena encountered are being labelled as "cold fusion" even if they are not, in order to attract the attention of journalists. In February 2012, millionaire Sidney Kimmel, convinced that cold fusion was worth investing in by a 19 April 2009 interview with physicist Robert Duncan on the US news show 60 Minutes, made a grant of $5.5 million to the University of Missouri to establish the Sidney Kimmel Institute for Nuclear Renaissance (SKINR).
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.